Screener
iRadimed IRMD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by iRadimed in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: iRadimed’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029325
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Dividends paid | (2,556) | (2,162) |
| Taxes paid related to the net share settlement of equity awards | (50) | (116) |
| Net cash used in financing activities | (2,606) | (2,278) |
| Net increase (decrease) in cash and cash equivalents | 5,215 | (1,903) |
| Cash and cash equivalents, beginning of period | 51,159 | 52,234 |
| Cash and cash equivalents, end of period | $56,374 | $50,331 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for income taxes | $14 | $9 |
Item 1. Condensed Financial Statements
FAQ
- What is iRadimed's cash & equivalents?
- iRadimed (IRMD) reported cash & equivalents of $56.37M in Q1 2026.
- How has iRadimed's cash & equivalents changed year-over-year?
- iRadimed's cash & equivalents increased by 12.0% year-over-year, from $50.33M to $56.37M.
- What is the long-term trend for iRadimed's cash & equivalents?
- Over 5 years (2020 to 2025), iRadimed's cash & equivalents has grown at a 0.4% compound annual growth rate (CAGR), from $50.07M to $51.16M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about iRadimed's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude